Lenalidomide (Revlimid) combined with continuous oral cyclophosphamide (endoxan) and prednisone (REP) is effective in lenalidomide/dexamethasone-refractory myeloma.

N.W.C.J. van de Donk; S. Wittebol; M.C. Minnema; H.M. Lokhorst

Lenalidomide (Revlimid) combined with continuous oral cyclophosphamide (endoxan) and prednisone (REP) is effective in lenalidomide/dexamethasone-refractory myeloma.

Translated title of the contribution: Lenalidomide (Revlimid) combined with continuous oral cyclophosphamide (endoxan) and prednisone (REP) is effective in lenalidomide/dexamethasone-refractory myeloma.

N.W.C.J. van de Donk, S. Wittebol, M.C. Minnema, H.M. Lokhorst

Research output: Contribution to journal › Article › Academic › peer-review

Translated title of the contribution	Lenalidomide (Revlimid) combined with continuous oral cyclophosphamide (endoxan) and prednisone (REP) is effective in lenalidomide/dexamethasone-refractory myeloma.
Original language	Undefined/Unknown
Pages (from-to)	335-337
Number of pages	3
Journal	British Journal of Haematology
Volume	148
Issue number	2
Publication status	Published - 2010

Cite this

@article{d868e0c980264380a5882cc6be889b79,

title = "Lenalidomide (Revlimid) combined with continuous oral cyclophosphamide (endoxan) and prednisone (REP) is effective in lenalidomide/dexamethasone-refractory myeloma.",

author = "{van de Donk}, N.W.C.J. and S. Wittebol and M.C. Minnema and H.M. Lokhorst",

year = "2010",

language = "Undefined/Unknown",

volume = "148",

pages = "335--337",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "Wiley-Blackwell",

number = "2",

}

Lenalidomide (Revlimid) combined with continuous oral cyclophosphamide (endoxan) and prednisone (REP) is effective in lenalidomide/dexamethasone-refractory myeloma. / van de Donk, N.W.C.J.; Wittebol, S.; Minnema, M.C. et al.
In: British Journal of Haematology, Vol. 148, No. 2, 2010, p. 335-337.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Lenalidomide (Revlimid) combined with continuous oral cyclophosphamide (endoxan) and prednisone (REP) is effective in lenalidomide/dexamethasone-refractory myeloma.

AU - van de Donk, N.W.C.J.

AU - Wittebol, S.

AU - Minnema, M.C.

AU - Lokhorst, H.M.

PY - 2010

Y1 - 2010

M3 - Article

SN - 0007-1048

VL - 148

SP - 335

EP - 337

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 2

ER -